Lv2
170 积分 2023-09-30 加入
Breast Cancer Statistics, 2022
4天前
已完结
Tisotumab Vedotin: First Approval
4天前
已完结
Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends
10天前
已完结
Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
26天前
已完结
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
26天前
已完结
BDTX-1535 Goes after Osimertinib Resistance
27天前
已完结
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
28天前
已完结
Surgical results for small cell lung cancer based on the new TNM staging system
1个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
1个月前
已完结
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
2个月前
已完结
皖公网安备34019202002308
